Opthea’s Baldwin Gives Update on Clinical Data for OPT-302

Megan Baldwin, PhD, CEO and managing director, Opthea Ltd., introduces OPT-302, a new vehicle for targeting the VEGF pathway and wet age-related macular degeneration (AMD). Baldwin says early clinical trial results are “very encouraging,” particularly in patients who have been treated previously with other drugs.


Megan Baldwin

Megan Baldwin

Dr Megan Baldwin is CEO/Managing Director of Opthea Limited and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases.

View Full Profile